A nonprofit health system based in Phoenix, operating 33 hospitals across six states
A body of studies is showing that a blood marker called p-tau217 can forecast an elevated risk of cognitive impairment in healthy older adults years before symptoms appear. The evidence is not yet clinical-ready, but it is guiding trials that aim to slow or prevent Alzheimer’s disease and is being tested in Scotland’s primary care setting.
The FDA has cleared four blood tests to help diagnose Alzheimer's in people with memory problems, a move that could speed access to therapies. Experts caution that tests are not for asymptomatic individuals, and many questions remain about accuracy. Readers are advised to focus on brain-healthy risks like blood pressure, diabetes and smoking.